Catalog Systems Vertical / domain-specific AI memory BenevolentAI

BenevolentAI

https://www.benevolent.com/

Taken private: merged into Osaka Holdings (renamed BenevolentAI S.A.) and delisted from Euronext Amsterdam 2025-03-13. Target identification / drug repurposing / mechanism tracing. 85+ data sources, petabyte-scale, rebuilt every few weeks. Wet-lab results re-enter the graph and shift downstream predictions — institutional experimental memory closing a feedback loop. As of Oct 2026 benevolent.com leads with Qor, powered by BenevolentAI, a life-science intelligence service for biopharma decision makers and consultancies. Qor (qor.one) is a continuously updated decision-intelligence service built on BenevolentAI's knowledge graph and reasoning methods: it tracks evidence on an asset or indication (competitive position, rival readouts, comparable deals), source-verifies each claim and flags when an earlier conclusion stops holding. It targets biotech teams and life-science consultancies.

Active · Verified 2026-10-29 · fresh as of 2026-10-29 · 34 cited facts, 7 with a third-party source · 2 recorded changes · Suggest a correction

At a glance

Type
Continuously-refreshed biological KG vendor fix
Tier
T1
Section
Vertical / domain-specific AI memory
Created
2013 (founded 2013 by Kenneth Mulvany) vendor fix
Latest release
not applicable — not OSS fix
License
not applicable — not OSS fix
GitHub
not applicable — no GitHub repo fix
Pricing
Qor: free trial (Try Qor for free) plus demo-led enterprise sales; no public price list third-party fix
Funding
$550M total raised (pre-merger); merged into Osaka Holdings (renamed BenevolentAI S.A.) and delisted from Euronext Amsterdam 2025-03-13 third-party fix
Freshness
2026-10-29 fix
Layer
agent-infra repo fix
Licensing
commercial third-party fix
Deployment locus
cloud third-party fix
Platform vs product
product vendor fix

Memory taxonomy

storage
graph
retrieval
graph-traversal
persistence
long-term
update
extraction
unit
fact
governance
inspectable
conflict
overwrite

When to use

Optimised for: research-workflow integration + provenance + claim grounding

Anti-fit: not for non-research / non-academic use cases

Pros & cons

Pros

Long-running drug-discovery KG with established pharma partnerships — memory is paired with experimental decision support, not just retrieval.

Cons

Drug-discovery scope only; commercial/subscription model; investor-facing pivots have introduced strategic uncertainty.

Claims & capabilities

AstraZeneca, Merck KGaA, Eli Lilly partners. Went private via Osaka Holdings merger in 2025.

Technical surface

API surface
searched not found
Backend storage
searched not found
Deployment
Managed-only
Embedding model
searched not found
Multi-tenancy
searched not found
MCP
no MCP support advertised — vertical product, no MCP server / client integration documented
A2A
no A2A protocol support advertised — vertical product, no A2A integration documented
OpenTelemetry
no OpenTelemetry integration advertised — vendor logs/observability not publicly documented

Compare BenevolentAI with…

Alternatives to BenevolentAI → live options ranked by shared design, licence, hosting and MCP support

Similar systems

Other vertical / domain-specific ai memory in the catalog, ranked by inbound references.

  • Inworld AI T1

    Formerly an NPC character engine with named Long-Term Memory; now sells realtime voice models (TTS-2, STT-1, speech-to-speech) and OpenAI-compatible open-model inference. Character/NPC memory is no longer the headline product.

  • NVIDIA ReMEmbR T3

    Builds long-horizon memory by captioning video segments with VILA, storing captions with timestamps + 3D position coordinates in MilvusDB. At query time, LLM iterates retrieval across text, time, and position modalities. Deployed on Nova Carter robot (Jetson Orin).

  • Abridge T1

    Clinician-assist ambient documentation. Source mapping: every AI-generated summary element traced back to the source utterance. Audit-and-trust layer over episodic memory. Built on proprietary 1.5M+ medical-encounter dataset.

  • ASAPP GenerativeAgent T1

    Treats memory as first-class architecture. Captures the digital footprint of every interaction; retrieves preference and history at engagement time. Public example: airline knowing a frequent flyer wants aisle seats with her son — preference-aware, not just history-lookup.

  • Causaly T1

    Agentic AI platform for life sciences: orchestrated scientific agents over a curated biomedical knowledge graph (plus Bio Graph and Pipeline Graph), an evidence-retrieval system and an enterprise data fabric over literature, trials and patents.

  • Character.ai T1

    Chat Memories (user-defined facts), auto-memories for c.ai+ subscribers, pinned memories, in-context retention. Latest chat models PipSqueak 3 and ShortSqueak (Sep 2026). On 2026-10-12 the company announced a voluntary Chapter 11 process for a court-supervised sale of all or substantially all assets (sale expected late Nov/early Dec 2026); the platform keeps running meanwhile and would be wound down if no viable bid emerges.

Sources (33 cited facts, 7 third-party)

Each fact links to the page it came from; the badge says who published it (how to read sources).

What changed

Changes to this record's lifecycle, licence, release, pricing and hosting facts, from the catalog's git history. Subscribe (Atom)

  1. 2026-10-29
    • Pricing “Enterprise only” → “Qor: free trial (Try Qor for free) plus demo-led enterprise sales; no public price list” source
    #309
  2. 2026-10-22
    • Funding / ownership “$550M total raised; acquired by Osaka Holdings Mar 2025” → “$550M total raised (pre-merger); merged into Osaka Holdings (renamed BenevolentAI S.A.) and delisted from Euronext Amsterdam 2025-03-13” source
    #195